This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tariquidar
- DrugBank Accession Number
- DB06240
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Tariquidar (DB06240)
- Weight
- Average: 646.744
Monoisotopic: 646.27913496 - Chemical Formula
- C38H38N4O6
- Synonyms
- Tariquidar
- External IDs
- XR-9576
- XR9576
Pharmacology
- Indication
Investigated for use/treatment in ovarian cancer, lung cancer, and breast cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Tariquidar is an anthranilic acid derivative third generation P-glycoprotein (P-gp) inhibitors. P-gp is a transport protein found in normal cells that has many trasport and modulatory functions, from affecting the distribution and bioavailability of drugs to mediating the migration of dendritic cells. P-gp is responsible for multidrug resistance through transport of anti-cancer drugs out of their target cells. It is proposed that tariquidar's and its derivatives may bind to the H-binding site of P-gp through multiple mechanisms of binding.
Target Actions Organism UP-glycoprotein 1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Tariquidar. Afatinib The serum concentration of Afatinib can be increased when it is combined with Tariquidar. Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Tariquidar. Apixaban The serum concentration of Apixaban can be increased when it is combined with Tariquidar. Avanafil The serum concentration of Avanafil can be increased when it is combined with Tariquidar. Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Tariquidar. Axitinib The serum concentration of Axitinib can be increased when it is combined with Tariquidar. Belantamab mafodotin The serum concentration of Belantamab mafodotin can be increased when it is combined with Tariquidar. Belinostat The serum concentration of Belinostat can be increased when it is combined with Tariquidar. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Tariquidar. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Anilides
- Direct Parent
- Benzanilides
- Alternative Parents
- Quinoline-3-carboxamides / Dimethoxybenzenes / Tetrahydroisoquinolines / Benzamides / Methoxyanilines / Phenethylamines / Pyridinecarboxylic acids and derivatives / Anisoles / Benzoyl derivatives / Phenoxy compounds show 11 more
- Substituents
- Alkyl aryl ether / Amine / Amino acid or derivatives / Anisole / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzamide / Benzanilide / Benzoic acid or derivatives show 29 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- J58862DTVD
- CAS number
- 206873-63-4
- InChI Key
- LGGHDPFKSSRQNS-UHFFFAOYSA-N
- InChI
- InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)
- IUPAC Name
- N-[2-({4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}carbamoyl)-4,5-dimethoxyphenyl]quinoline-3-carboxamide
- SMILES
- COC1=CC2=C(CN(CCC3=CC=C(NC(=O)C4=CC(OC)=C(OC)C=C4NC(=O)C4=CN=C5C=CC=CC5=C4)C=C3)CC2)C=C1OC
References
- General References
- Muller H, Pajeva IK, Globisch C, Wiese M: Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62. Epub 2007 Nov 28. [Article]
- Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R: The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol. 1999 Sep;128(2):403-11. [Article]
- External Links
- ChemSpider
- 130650
- BindingDB
- 50075373
- ChEMBL
- CHEMBL348475
- ZINC
- ZINC000004214704
- PDBe Ligand
- R1H
- Wikipedia
- Tariquidar
- PDB Entries
- 7a6e / 7neq
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Terminated Not Available Advanced Non Small Cell Lung Cancer (NSCLC) / Stage IIIB Non Small Cell Lung Cancer 2 2 Completed Diagnostic Cancer 1 2 Completed Treatment Adrenal Cortex Neoplasms 1 2 Completed Treatment Neoplasm Cervix / Neoplasms, Lung / Neoplasms, Ovarian / Renal Neoplasms 1 2 Completed Treatment Neoplasms, Breast 1 1 Completed Treatment Adenaocortical Carcinoma / Coldrhood Cancer / Refractory Cancer / Sarcomas / Wilms' tumor 1 1 Completed Treatment Breast Cancer / Cancer / Lung Cancers / Ovarian Cancer 1 1 Terminated Other Neuropathic Pain 1 1, 2 Recruiting Treatment Neuropathic Pain 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00202 mg/mL ALOGPS logP 5.26 ALOGPS logP 5.68 ChemAxon logS -5.5 ALOGPS pKa (Strongest Acidic) 11.45 ChemAxon pKa (Strongest Basic) 8.36 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 111.25 Å2 ChemAxon Rotatable Bond Count 11 ChemAxon Refractivity 188.12 m3·mol-1 ChemAxon Polarizability 70.07 Å3 ChemAxon Number of Rings 6 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- NCATS: Tariquidar [Link]
Drug created at March 19, 2008 16:19 / Updated at February 21, 2021 18:52